1. Home
  2. Browse
  3. HRA011494
HRA011494
   HRA011494.xlsx
Title:
Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial
Release date:
2025-05-15
Description:
This multicenter, phase II trial (CHESS) evaluated the safety and efficacy of zanubrutinib plus rituximab induction therapy followed by shortened chemoimmunotherapy in previously untreated mantle cell lymphoma (MCL) patients. The results showed a high complete response (CR) rate of 88% at the completion of the induction phase, with a 2-year progression-free survival and overall survival rate of 85% and 90%, respectively. Transcriptomic analyses identified three MCL molecular subtypes with distinct treatment responses, providing insights for future personalized treatment strategies.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA040041
Study type:
Cohort Study
Disease name:
mantle cell lymphoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC005979
DAC name:
mantle cell lymphoma
Contact person:
Cai Qingqing
Email:
caiqq@sysucc.org.cn
Description:
This multicenter, phase II trial (CHESS) evaluated the safety and efficacy of zanubrutinib plus rituximab induction therapy followed by shortened chemoimmunotherapy in previously untreated mantle cell lymphoma (MCL) patients.
Individuals & samples
Files
Request Data
Submitter:   Cai Qingqing / caiqq@sysucc.org.cn
Organization:   Sun Yat-sen University Cancer Center
Submission date:   2025-05-12
Requests:   -